Ascentage Pharma Group International (NASDAQ:AAPG - Get Free Report) shares hit a new 52-week high on Monday . The company traded as high as $29.72 and last traded at $29.71, with a volume of 35167 shares trading hands. The stock had previously closed at $28.38.
Analyst Ratings Changes
Separately, JPMorgan Chase & Co. assumed coverage on Ascentage Pharma Group International in a report on Thursday, March 27th. They issued an "overweight" rating on the stock.
Read Our Latest Analysis on AAPG
Ascentage Pharma Group International Price Performance
The firm's 50 day moving average price is $23.80.
Institutional Investors Weigh In On Ascentage Pharma Group International
A hedge fund recently bought a new stake in Ascentage Pharma Group International stock. Monashee Investment Management LLC acquired a new position in shares of Ascentage Pharma Group International (NASDAQ:AAPG - Free Report) in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 159,942 shares of the company's stock, valued at approximately $3,511,000. Monashee Investment Management LLC owned 0.18% of Ascentage Pharma Group International at the end of the most recent quarter.
About Ascentage Pharma Group International
(
Get Free Report)
Ascentage Pharma Group International Co, Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.
Further Reading
Before you consider Ascentage Pharma Group International, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ascentage Pharma Group International wasn't on the list.
While Ascentage Pharma Group International currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
